Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

PDS Biotechnology Corporation PDSB

Healthcare  —  Biotechnology
0.80 0.00 0.00% as of 25 Sep
Market cap
$44.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

PDS Biotechnology Corporation (PDSB) Business Profile

Updated before January 2025

Company Overview

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies for cancer and infectious diseases. Founded in 2005 and headquartered in Florham Park, New Jersey, PDSB leverages its proprietary Versamune® platform to develop innovative therapies that activate the immune system to combat diseases. The company is led by a team of experienced professionals, including Dr. Frank Bedu-Addo, who serves as the President and Chief Executive Officer. Dr. Bedu-Addo brings decades of experience in biotechnology and pharmaceutical development, steering the company toward groundbreaking advancements in immunotherapy.

Core Business Segments

PDS Biotechnology focuses on two primary areas: cancer immunotherapy and infectious disease vaccines. These segments are powered by the company’s proprietary Versamune® platform, which enhances the delivery and effectiveness of therapeutic agents.

Cancer Immunotherapy

PDSB’s cancer immunotherapy pipeline includes multiple clinical-stage candidates targeting various cancers. Key products include:

  • PDS0101: A lead candidate designed to treat HPV-associated cancers, including head and neck, cervical, and anal cancers. PDS0101 is currently in multiple Phase 2 clinical trials.
  • PDS0102 and PDS0103: These candidates target other tumor-associated antigens and are in preclinical development.

Infectious Disease Vaccines

PDSB is also leveraging its Versamune® platform to develop vaccines for infectious diseases. Key products include:

  • PDS0203: A COVID-19 vaccine candidate designed to provide long-lasting immunity by activating both T-cells and antibodies.
  • Other Vaccine Candidates: The company is exploring vaccines for other infectious diseases, including influenza and respiratory syncytial virus (RSV).

Business Model

PDS Biotechnology operates on a research-driven business model, focusing on the development and commercialization of immunotherapies. The company generates revenue through partnerships, licensing agreements, and potential future product sales. By collaborating with academic institutions, government agencies, and pharmaceutical companies, PDSB accelerates its research and development efforts while minimizing costs. The company also seeks to out-license its Versamune® platform to other biotech firms, creating additional revenue streams.

Strategic Direction

PDSB aims to become a leader in immunotherapy by advancing its clinical pipeline and expanding its Versamune® platform applications. Key strategic goals include:

  • Pipeline Expansion: The company plans to develop additional candidates targeting new cancer types and infectious diseases.
  • Regulatory Approvals: PDSB is focused on advancing its lead candidates through clinical trials and obtaining FDA and global regulatory approvals.
  • Partnerships and Collaborations: The company seeks to establish new partnerships to co-develop and commercialize its products.
  • Sustainability Goals: PDSB is committed to sustainable practices in its research and manufacturing processes, aiming to minimize its environmental footprint.

Competitive Landscape

PDS Biotechnology operates in a highly competitive biopharmaceutical sector. Key competitors include:

  • Moderna, Inc.: Known for its mRNA-based vaccines and immunotherapies.
  • BioNTech SE: A leader in cancer immunotherapy and infectious disease vaccines.
  • Inovio Pharmaceuticals, Inc.: Focused on DNA-based immunotherapies.
  • Gilead Sciences, Inc.: A major player in oncology and infectious disease treatments.

Despite the competition, PDSB differentiates itself through its proprietary Versamune® platform, which offers unique advantages in immune activation and therapeutic efficacy.

Risk Factors

PDS Biotechnology faces several risks that could impact its operations and financial performance:

  • Clinical Trial Risks: The success of PDSB’s pipeline depends on positive clinical trial outcomes, which are inherently uncertain.
  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals could hinder product commercialization.
  • Market Dependence: The company relies heavily on its lead candidate, PDS0101, for future revenue.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of raw materials and manufacturing processes.
  • Competitive Pressure: Intense competition from established players could limit market share and revenue growth.

Recent Developments

PDS Biotechnology has made significant progress in recent years:

  • Clinical Trial Advancements: PDS0101 has shown promising results in Phase 2 trials, demonstrating improved survival rates and tumor reduction in HPV-associated cancers.
  • Partnerships: The company has entered into collaborations with the National Cancer Institute (NCI) and MD Anderson Cancer Center to accelerate its research.
  • COVID-19 Vaccine Development: PDS0203 has advanced to preclinical studies, showcasing the versatility of the Versamune® platform.
  • Corporate Strategy: PDSB has strengthened its leadership team and secured additional funding to support its pipeline development.

Investment Considerations

Strengths

  • Innovative Technology: The Versamune® platform offers a competitive edge in immunotherapy development.
  • Diverse Pipeline: PDSB’s focus on both cancer and infectious diseases provides multiple revenue opportunities.
  • Strong Partnerships: Collaborations with leading institutions enhance credibility and accelerate R&D efforts.

Risks

  • Early-Stage Company: As a clinical-stage company, PDSB has no approved products and relies on external funding.
  • Regulatory and Clinical Risks: Delays or failures in trials and approvals could impact growth.
  • Market Competition: The biopharmaceutical sector is highly competitive, with numerous well-funded players.

Conclusion

PDS Biotechnology Corporation is a promising player in the biopharmaceutical industry, leveraging its proprietary Versamune® platform to develop innovative immunotherapies. While the company faces challenges typical of early-stage biotech firms, its strong pipeline, strategic partnerships, and focus on cutting-edge technology position it for long-term success. Investors should weigh the potential rewards against the inherent risks, keeping an eye on clinical trial outcomes and regulatory milestones. With a clear strategic direction and a commitment to innovation, PDSB is well-positioned to make a significant impact in the fields of oncology and infectious diseases.